Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases
Case seriesHumans
- Design
- Case series
- Subjects
- 2 autistic women with different levels of support need
- Dose used in the study
- 600 mg a day of ultramicronised palmitoylethanolamide, with no other medication
- Duration
- 4 months, with follow-up to 36 weeks
- What was measured
- Distress and mood questionnaires, daily functioning, blood markers of inflammation and endocannabinoid levels
What the authors reported
This case series found:
- One patient had improved depressive symptoms and social engagement, with lower inflammatory markers, partially relapsing after the supplement was stopped at 4 months.
- The other was stable at first, then deteriorated and needed an antipsychotic.
- No adverse events were reported.
Limits of this study
Two cases with opposite courses. The authors call the report exploratory and note self-assessment bias. The study had no funding, and the product was supplied by its maker, Epitech Group.
Source
PubMed 39502301 · doi:10.3389/fpsyt.2024.1463849
Entry checked against the full text at the publisher (Frontiers) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.